期刊文献+

吉非替尼有关物质的合成 被引量:2

Synthesis of Related Substances of Gefi tinib
原文传递
导出
摘要 为控制吉非替尼的质量,分别合成了质量标准中所载的4个有关物质:N-(3-氯-4-氟苯基)-7-甲氧基-6-[3-(吗啉-4-基)丙氧基]-N-[3-(吗啉-4-基)丙基]喹唑啉-4-胺(A),N-(3-氟-4-氯苯基)-7-甲氧基-6-[3-(吗啉-4-基)丙氧基]喹唑啉-4-胺(B),7-甲氧基-6-[3-(吗啉-4-基)丙氧基]喹唑啉-4(3H)-酮(C),N-(3,4-二氯苯基)-7-甲氧基-6-[3-(吗啉-4-基)丙氧基]喹唑啉-4-胺(D),并经1H NMR、13C NMR、MS等确证结构。 To perform the quality control of the gefitinib,four related substances recorded in quality specifications were prepared,and their structures were confirmed by 1H NMR,13C NMR and MS.These substances were N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl) propoxy]-N-[3-(morpholin-4-yl) propyl) quinazolin-4-amine (A),N-(4-chloro-3-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl) propoxy] quinazolin-4-amine (B),7-methoxy-6-[3-(morpholin-4-yl) propoxy] quinazolin-4 (3H)-one (C),and N-(3,4-dichlorophenyl)-7-methoxy-6-[3-(morpholin-4-yl) propoxy] quinazolin-4-amine (D).
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2014年第6期513-516,共4页 Chinese Journal of Pharmaceuticals
关键词 吉非替尼 有关物质 合成 gefitinib related substance synthesis
  • 相关文献

参考文献9

二级参考文献72

  • 1吴一龙.肺癌分子靶向治疗的个体化[J].循证医学,2004,4(2):67-68. 被引量:9
  • 2施春雷,韩宝惠.ASCO不可手术切除的非小细胞肺癌治疗指南——2003新版推荐指南[J].循证医学,2004,4(2):115-124. 被引量:114
  • 3张艳华,宁华,姜洋.表皮生长因子受体酪氨酸激酶抑制剂吉非替尼[J].中国新药杂志,2004,13(10):947-950. 被引量:13
  • 4杨学宁,廖日强,吴一龙,陈刚.NCCN非小细胞肺癌临床指引2004/2005版更新[J].循证医学,2004,4(4):252-256. 被引量:9
  • 5张竹霞,吕荣文,张珂珂,高昆玉.水合肼还原芳硝基物的研究[J].精细化工,2001,18(4):239-242. 被引量:54
  • 6[3]D'Amico TA,Massey M,Herndon JE II,et al.A biologic risk model for stage I lung cancer:Immunohistochemical analysis of 408 patients with the use of ten molecular markers.J Thorac Cardiovasc Surg,1999,117:736~743
  • 7[4]Albanell J,Codony-Servat J,Rojo F,et al.Activated extracellular signal-regulated kinases:Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.Cancer Res,2001,61:6500~6510
  • 8[5]Moasser MM,Basso A,Averbuch SD,et al.The tyrosine kinase inhibitor ZD1839 inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.Cancer Res,2001,61:7184~7188
  • 9[6]Ciardiello F,Caputo R,Bianco R,et al.Antitumour effect and potentiation of cytotoxic drug activity in human cancer cells by ZD1839 (Iressa),an epidermal growth factor receptor-selective tyrosine kinase inhibitor.Clin Cancer Res,2000,6:2053~2063
  • 10[7]Herbst RS,Maddox AM,Rothenberg ML,et al.Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non-Small-Cell Lung Cancer and Other Solid Tumors:Results of a Phase I Trial.J Clin Oncol,2002,20(18):3815~3825

共引文献40

同被引文献6

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部